Literature DB >> 20563566

Letter to the editor: pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: impact of the 79A>C cytidine deaminase polymorphism.

Cédric Mercier, Laetitia Dahan, L'houcine Ouafik, Nicolas André, Joseph Ciccolini.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20563566     DOI： 10.1007/s00228-010-0859-5

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  5 in total

1.  Recombinant gene products of two natural variants of the human cytidine deaminase gene confer different deamination rates of cytarabine in vitro.

Authors:  H C Kirch; J Schröder; H Hoppe; H Esche; S Seeber; J Schütte
Journal:  Exp Hematol       Date:  1998-05       Impact factor: 3.084

2.  Pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: impact of the 79A>C cytidine deaminase polymorphism.

Authors:  Jan Gerard Maring; Floris M Wachters; Monique Slijfer; J Marina Maurer; H Marike Boezen; Donald R A Uges; Elisabeth G E de Vries; Harry J M Groen
Journal:  Eur J Clin Pharmacol       Date:  2010-03-06       Impact factor: 2.953

3.  Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients.

Authors:  Carmelo Tibaldi; Elisa Giovannetti; Enrico Vasile; Valentina Mey; Adrie C Laan; Sara Nannizzi; Roberta Di Marsico; Andrea Antonuzzo; Cinzia Orlandini; Simona Ricciardi; Mario Del Tacca; Godefridus J Peters; Alfredo Falcone; Romano Danesi
Journal:  Clin Cancer Res       Date:  2008-03-15       Impact factor: 12.531

4.  Cytidine deaminase residual activity in serum is a predictive marker of early severe toxicities in adults after gemcitabine-based chemotherapies.

Authors:  Joseph Ciccolini; Laetitia Dahan; Nicolas André; Alexandre Evrard; Muriel Duluc; Aurore Blesius; Chenguang Yang; Sarah Giacometti; Caroline Brunet; Caroline Raynal; Adrien Ortiz; Nicolas Frances; Athanassios Iliadis; Florence Duffaud; Jean-François Seitz; Cédric Mercier
Journal:  J Clin Oncol       Date:  2009-11-23       Impact factor: 44.544

5.  Gemcitabine pharmacogenomics: cytidine deaminase and deoxycytidylate deaminase gene resequencing and functional genomics.

Authors:  Judith A Gilbert; Oreste E Salavaggione; Yuan Ji; Linda L Pelleymounter; Bruce W Eckloff; Eric D Wieben; Matthew M Ames; Richard M Weinshilboum
Journal:  Clin Cancer Res       Date:  2006-03-15       Impact factor: 12.531
  5 in total
  1 in total

Review 1.  Integrating pharmacogenetics into gemcitabine dosing--time for a change?

Authors:  Joseph Ciccolini; Cédric Mercier; Laetitia Dahan; Nicolas André
Journal:  Nat Rev Clin Oncol       Date:  2011-02-08       Impact factor: 66.675
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.